CN104324036A - Drug composition of sulfamonomethoxine sodium with synergistic antibacterial effect for injection - Google Patents
Drug composition of sulfamonomethoxine sodium with synergistic antibacterial effect for injection Download PDFInfo
- Publication number
- CN104324036A CN104324036A CN201410611974.3A CN201410611974A CN104324036A CN 104324036 A CN104324036 A CN 104324036A CN 201410611974 A CN201410611974 A CN 201410611974A CN 104324036 A CN104324036 A CN 104324036A
- Authority
- CN
- China
- Prior art keywords
- injection
- pharmaceutical composition
- pvp
- sodium
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a drug composition of sulfamonomethoxine sodium with synergistic antibacterial effect for injection. The drug composition comprises the following components in parts by weight: 1-5 parts of sulfamonomethoxine sodium, 1-2 parts of trimethoprim, 2-5 parts of PLGA, 1-3 parts of PEG, 1-2 parts of PVP, 0.5-1 part of mannitol, 0.5-1 part of glycine, 0.5-1 part of poloxamer and 1-3 parts of ethylene glycol. The drug composition disclosed by the invention has the advantages of high drug stability, good solubility, simple preparation process, good staphylococcus aureus and gram-negative bacterium inhibition effect and definite treatment effect and is capable of reducing the usage amount of a prescription preparation and shortening the treatment period.
Description
Technical field
The present invention relates to the compound preparation of a kind of sulfa drugs and trimethoprim (TMP), especially a kind of pharmaceutical composition of injection sulfamonomethoxine sodium.
Background technology
Sulfa drugs (Sulfonamides, SAs) refers to the general name of a class medicine with P-aminobenzene-sulfonamide structure, is the chemotherapeutic agent of a class for prevention and therapy bacterial infection disease.SAs kind can reach thousands of kinds, wherein apply comparatively wide and there is certain curative effect just have tens kinds.Sulphonamides is antibacterial and antiphlogistic medicine conventional in modern medicine, and it is various in style, has become huge " family "., sulfanilamide the earliest is but a member in dyestuff.Sulfa drugs can suppress gram positive bacteria and some negative bacterium.Have its extremely sensitive antibacterial: streptococcus, streptococcus pneumoniae, Salmonella, corynebacterium pyogenes, escherichia coli.There is inhibitory action to staphylococcus, pneumobacillus, pasteurellosis bacillus, anthrax bacillus, Shiga bacillus, Arizona bacterium etc., also have effect to some protozoon of harm poultry.
Sulfonamides Main Function is the breeding of anti-bacteria, during because of some bacterial growth, need utilize para-amino benzoic acid.Amino benzoic Acid and dihydro pteridine under the effect of dihydrofolate synthetase, synthesizing dihydro folic acid; Dihydrofoilic acid, under the effect of dihydrofolate reductase, generates tetrahydrofolic acid again; Tetrahydrofolic acid forms activated form tetrahydrofolic acid more further, namely coenzyme F, and it can transmit a carbon-based group and participate in purine, pyrimidine nucleotide synthesis.Due to chemical constitution and the amino benzoic Acid very elephant of sulfonamides, dihydrofolate synthetase can be competed with aminobenzoic acid, hinder the formation of dihydrofoilic acid, finally affect the synthesis of antibacterial nucleoprotein, thus the growth and breeding of anti-bacteria.To the antibacterial of sulfonamides sensitivity, all can obtain drug resistance in vivo and in vitro, and after drug resistance is produced to a kind of sulfanilamide, also often cross resistance is produced to other sulfanilamide, but the antibacterial of resistance to sulfonamides be still responsive to other antibacterials.Therefore, the normal and trimethoprim (TMP) conjunctive use of sulfa drugs is to overcome its drug resistance.
Summary of the invention
The invention provides a kind of medicinal composition for injections comprising cefathiamidine and sodium-tazobactam with synergetic antibacterial effect, to staphylococcus aureus, staphylococcus epidermidis, enterococcus faecalis has good inhibitory action, greatly reduces the consumption of single preparations of ephedrine; This injection has the features such as solubility is good, good stability, and drug loading is high, safety of clinical trials is good, overcomes the deficiencies in the prior art part.
Have a pharmaceutical composition for the injection sulfamonomethoxine sodium of synergetic antibacterial effect, in compositions, the parts by weight of each component are: sulfametoxydiazine sodium 1-5 part; Trimethoprim 1-2 part; PLGA 2-5 part; PEG 1-3 part; PVP 1-2 part; Glycine 0.5-1 part; Poloxamer 0.5-1 part; Ethylene glycol 1-3 part.Described PLGA molecular weight is between 5000-20000, and wherein the polymer thing ratio of lactic acid and hydroxyacetic acid is 40::90-35:65.
As preferably, the weight ratio of described sulfametoxydiazine sodium and trimethoprim is 0.5:1-1:2.
As preferably, PLGA is 4-6 part.
As preferably, described poloxamer is selected from PLURONICS F87 or Pluronic/Lutrol F 44.
As preferably, described PVP is selected from PVP k10, the one in PVP k17 or PVP k30.
As preferably, described PEG is selected from PEG400 or PEG600.
The preparation method of the pharmaceutical composition of described injection sulfamonomethoxine sodium, comprises the steps:
(1) each component is taken by formula proportion;
(2) sulfamonomethoxine sodium, PEG and trimethoprim are added successively in water for injection, stirring and dissolving obtains interior aqueous phase W1;
(3) PLGA, poloxamer being dissolved in volume ratio is in the dichloromethane/acetone of 3: 1, obtains oil phase;
(4) PVP, ethylene glycol and glycine are added in water for injection to be stirred to dissolve completely, obtain outer aqueous phase W2;
(5) under agitation slowly added in oil phase by W1, under ice bath, supersound process 20s obtains colostrum; Slowly added in W2 by colostrum and stir 10min and obtain emulsion, poured into by emulsion in the aqueous solution for injection of sodium chloride, ice bath stirs 4h volatile residue organic solvent, and collect microsphere by 0.45 μm of filtering with microporous membrane, water for injection washs 3 times, vacuum lyophilization.
Compared with the prior art, pharmaceutical composition of injection sulfamonomethoxine sodium provided by the invention and trimethoprim and preparation method thereof, has the following advantages:
1, good stability: the pharmaceutical composition of sulfamonomethoxine sodium provided by the invention and trimethoprim, wrapped up and be adsorbed in nanoparticulate carriers material, its active component is effectively protected, therefore the more excellent commercially available product of stability is more excellent.Acceleration June and long-time stability are investigated result and are also shown that solution colour, pH value, related substance, content all do not have significant change, and envelop rate is good, drastically increases medicine stability.
2, solubility is good, Save Range is wide: the employing of Freeze Drying Technique effectively avoids the degraded of polymeric material, medicine is revealed or drug degradation, make medicine preservation condition wider, solubility is good, and after redissolving, the various physicochemical property of medicine is substantially identical with before lyophilizing.
3, antibacterial activity is high: in the present invention, sulfamonomethoxine sodium and trimethoprim coordinate with specific ratio, can produce cooperative effect, when reducing dosage, farthest plays Antifungal activity.
Detailed description of the invention
Embodiment 1: a kind of pharmaceutical composition of injection sulfamonomethoxine sodium
Sulfamonomethoxine sodium, PEG and trimethoprim are added successively in 1000mL water for injection, stirring and dissolving obtains interior aqueous phase W1; It is in the 1000mL dichloromethane/acetone of 3: 1 that PLGA (molecular weight be 6000, LA:GA polymerization than for 50:50), poloxamer are dissolved in volume ratio, obtains oil phase;
(4) PVP, ethylene glycol and glycine are added in water for injection to be stirred to dissolve completely, obtain outer aqueous phase W2;
(5) under agitation slowly added in oil phase by W1, under ice bath, supersound process 20s obtains colostrum; Colostrum is slowly added in W2 and stirs 10min and obtain emulsion, poured into by emulsion in the aqueous solution for injection of 2000mL sodium chloride, ice bath stirs 4h volatile residue organic solvent, collects microsphere by 0.45 μm of filtering with microporous membrane, water for injection washs 3 times, vacuum lyophilization.
Embodiment 2: a kind of pharmaceutical composition of injection sulfamonomethoxine sodium
Sulfamonomethoxine sodium, PEG and trimethoprim are added successively in 1000mL water for injection, stirring and dissolving obtains interior aqueous phase W1; It is in the 1000mL dichloromethane/acetone of 3: 1 that PLGA (molecular weight be 5000, LA:GA polymerization than for 50:50), poloxamer are dissolved in volume ratio, obtains oil phase;
(4) PVP, ethylene glycol and glycine are added in water for injection to be stirred to dissolve completely, obtain outer aqueous phase W2;
(5) under agitation slowly added in oil phase by W1, under ice bath, supersound process 20s obtains colostrum; Colostrum is slowly added in W2 and stirs 10min and obtain emulsion, poured into by emulsion in the aqueous solution for injection of 2000mL sodium chloride, ice bath stirs 4h volatile residue organic solvent, collects microsphere by 0.45 μm of filtering with microporous membrane, water for injection washs 3 times, vacuum lyophilization.
Embodiment 3: a kind of pharmaceutical composition of injection sulfamonomethoxine sodium
Sulfamonomethoxine sodium, PEG and trimethoprim are added successively in 1000mL water for injection, stirring and dissolving obtains interior aqueous phase W1; It is in the 1000mL dichloromethane/acetone of 3:1 that PLGA (molecular weight be 5500, LA:GA polymerization than for 50:50), poloxamer are dissolved in volume ratio, obtains oil phase;
(4) PVP, ethylene glycol and glycine are added in water for injection to be stirred to dissolve completely, obtain outer aqueous phase W2;
(5) under agitation slowly added in oil phase by W1, under ice bath, supersound process 20s obtains colostrum; Colostrum is slowly added in W2 and stirs 10min and obtain emulsion, poured into by emulsion in the aqueous solution for injection of 2000mL sodium chloride, ice bath stirs 4h volatile residue organic solvent, collects microsphere by 0.45 μm of filtering with microporous membrane, water for injection washs 3 times, vacuum lyophilization.
Embodiment 4: droplet measurement
The injection of Example 1-3, is dissolved in water into the solution of every 1ml containing 1mg sulfamonomethoxine sodium, measures with laser diffraction particle size instrument.The injection of the cefathiamidine that acetonideexample 1-3 prepares and sodium-tazobactam is spherical shape, and even particle size distribution, whole particle diameter is between 350-650nm.
Embodiment 5: envelop rate detects
Sulfamonomethoxine sodium and the injection of trimethoprim are dissolved in water into the solution of every 1ml containing sulfamonomethoxine sodium 1mg, with the centrifugation 15min of 6000r/min, get supernatant 1mL, with dissolve with methanol, measure the content of sulfamonomethoxine sodium.
Dose in envelop rate=microsphere/(dose in the dose+medium in microsphere) × 100%
The envelop rate of injection prepared by embodiment 1-3, between 88%-95%.
Embodiment 6: dissolution velocity is investigated
Each two bottles of injection in random selecting embodiment 1-3, numbering 1-6, sample number into spectrum 7 after physical mixed, the sulfamonomethoxine sodium freeze-dried powder numbering 8 of having gone on the market, by the dissolving method of clinical application, inject 10ml water for injection respectively, eddy mixer jolts, completely clear and bright for index to dissolve, calculate dissolution velocity.
Experimental result shows that the dissolution velocity of injection of the present invention is obviously better than the injection of direct packaging.
Embodiment 7: study on the stability
The injection that the sample prepared by embodiment 1-3 and raw material directly mix subpackage is placed in high temperature 40 DEG C, lower 6 months of relative humidity 75% ± 5% condition respectively, carries out acceleration and investigates.
Claims (7)
1. have a pharmaceutical composition for the injection sulfamonomethoxine sodium of synergetic antibacterial effect, in compositions, the parts by weight of each component are:
Sulfametoxydiazine sodium 1-5 part;
Trimethoprim 1-2 part;
PLGA 2-5 part;
PEG 1-3 part;
PVP 1-2 part;
Glycine 0.5-1 part;
Poloxamer 0.5-1 part;
Ethylene glycol 1-3 part;
Described PLGA molecular weight is between 5000-20000, and wherein the polymer thing ratio of lactic acid and hydroxyacetic acid is 40:90-35:65.
2. pharmaceutical composition as claimed in claim 1, is characterized in that the weight ratio of described sulfametoxydiazine sodium and trimethoprim is 0.5:1-1:2.
3. pharmaceutical composition as claimed in claim 1, is characterized in that PLGA is 4-6 part.
4. pharmaceutical composition as claimed in claim 1, is characterized in that described poloxamer is selected from PLURONICS F87 or Pluronic/Lutrol F 44.
5. the pharmaceutical composition as described in claim arbitrary in claim 1-3, is characterized in that described PVP is selected from PVP k10, the one in PVP k17 or PVP k30.
6. pharmaceutical composition as claimed in claim 1, is characterized in that described PEG is selected from PEG400 or PEG600.
7. the preparation method of the pharmaceutical composition of injection sulfamonomethoxine sodium as described in claim arbitrary in claim 1-5, comprises the steps:
(1) each component is taken by formula proportion;
(2) sulfamonomethoxine sodium, PEG and trimethoprim are added successively in water for injection, stirring and dissolving obtains interior aqueous phase W1;
(3) PLGA, poloxamer being dissolved in volume ratio is in the dichloromethane/acetone of 3: 1, obtains oil phase;
(4) PVP, ethylene glycol and glycine are added in water for injection to be stirred to dissolve completely, obtain outer aqueous phase W2;
(5) under agitation slowly added in oil phase by W1, under ice bath, supersound process 20s obtains colostrum; Slowly added in W2 by colostrum and stir 10min and obtain emulsion, poured into by emulsion in the aqueous solution for injection of sodium chloride, ice bath stirs 4h volatile residue organic solvent, and collect microsphere by 0.45 μm of filtering with microporous membrane, water for injection washs 3 times, vacuum lyophilization.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410611974.3A CN104324036A (en) | 2014-11-04 | 2014-11-04 | Drug composition of sulfamonomethoxine sodium with synergistic antibacterial effect for injection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410611974.3A CN104324036A (en) | 2014-11-04 | 2014-11-04 | Drug composition of sulfamonomethoxine sodium with synergistic antibacterial effect for injection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104324036A true CN104324036A (en) | 2015-02-04 |
Family
ID=52398928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410611974.3A Pending CN104324036A (en) | 2014-11-04 | 2014-11-04 | Drug composition of sulfamonomethoxine sodium with synergistic antibacterial effect for injection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104324036A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114129510A (en) * | 2021-12-03 | 2022-03-04 | 聊城大学 | Compound sulfanilamide injection and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103006674A (en) * | 2012-12-14 | 2013-04-03 | 江苏恒丰强生物技术有限公司 | Compound sulfamonomethoxine sodium solution and preparation method thereof |
| CN103118670A (en) * | 2010-06-01 | 2013-05-22 | 欧鲁普雷图联邦大学 | Nanoparticulate composition containing antibiotics for intramammary administration in animals |
-
2014
- 2014-11-04 CN CN201410611974.3A patent/CN104324036A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103118670A (en) * | 2010-06-01 | 2013-05-22 | 欧鲁普雷图联邦大学 | Nanoparticulate composition containing antibiotics for intramammary administration in animals |
| CN103006674A (en) * | 2012-12-14 | 2013-04-03 | 江苏恒丰强生物技术有限公司 | Compound sulfamonomethoxine sodium solution and preparation method thereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114129510A (en) * | 2021-12-03 | 2022-03-04 | 聊城大学 | Compound sulfanilamide injection and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rashki et al. | Delivery LL37 by chitosan nanoparticles for enhanced antibacterial and antibiofilm efficacy | |
| CN106176617A (en) | Amoxicillin soluble powder and preparation method thereof | |
| EP2511345B1 (en) | Solubilization method for partially soluble / insoluble active substances through formation of oligomer composite | |
| CN109260177B (en) | Preparation method and application of berberine hydrochloride compound nanoparticles | |
| Wang et al. | Poly (lactide-co-glycolide) encapsulated hydroxyapatite microspheres for sustained release of doxycycline | |
| Zhou et al. | Co-precipitation of calcium carbonate and curcumin in an ethanol medium as a novel approach for curcumin dissolution enhancement | |
| CN107595782A (en) | A kind of Linezolid dry suspensoid agent and preparation method thereof | |
| Zhang et al. | Novel urea derivative-loaded PLGA nanoparticles to inhibit caries-associated Streptococcus mutans | |
| CN104324036A (en) | Drug composition of sulfamonomethoxine sodium with synergistic antibacterial effect for injection | |
| CN104873501A (en) | Sulbactam sodium composition for treating infectious diseases | |
| CN105560243B (en) | A kind of preparation method of piperacillin sodium injection sulbactam sodium composition | |
| CN103271925B (en) | Injection-use pharmaceutical composition comprising cefmetazole sodium and clavulanate potassium | |
| CN104398527A (en) | Sulfamethoxazole pharmaceutical composition for injection | |
| CN104324040A (en) | Pharmaceutical composition of sulfadimethoxine for injection | |
| CN104434933A (en) | Medicine composition containing sulfamethoxazole for injection | |
| CN101804060B (en) | Microsphere injection of ceftriaxone sodium/tazobactam sodium drug composition | |
| CN103271924B (en) | Injection-use pharmaceutical composition comprising cefathiamidine and tazobactam sodium | |
| CN102727451B (en) | Cefmetazole-containing pharmaceutical composition | |
| CN108272756A (en) | A kind of amoxicillin soluble powder and preparation method thereof | |
| CN109745546A (en) | Isotonic composition and preparation method thereof for improving teicopanin for injection stability | |
| CN101036657A (en) | Stable cefoperazone medicine prparation | |
| KR101473979B1 (en) | Pharmaceutical composition comprising marbofloxacin | |
| Kundu et al. | Formulation and characterization of alginate microbeads of norfloxacin by ionotropic gelation | |
| CN101810584B (en) | Microsphere injection of medicinal composition of cefotiam hydrochloride and anhydrous sodium carbonate | |
| CN104324034A (en) | Compound aminopyrine pharmaceutical composition for injection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150204 |
|
| RJ01 | Rejection of invention patent application after publication |